基本信息
views: 117
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Wen-Kai Weng specializes in the treatment of non-Hodgkin's lymphoma (NHL), his basic research interest is immunotherapy for lymphoma and cancer, with two components: tumor specific targeting therapy and allogeneic transplant. He is currently working on new strategies to target patient-specific tumor using antibody along with effector cells. He is also conducting clinical study looking at the clinical efficacy of allogeneic transplant in patients with cutaneous lymphoma.
Research Interests
Papers共 186 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
BLOOD ADVANCESno. 6 (2024): 1474-1486
Jay Spiegel,Jean S. Oak,Anmol Goyal, Scott Bornheimer, Allison Irvine,Rhine R. Shen,Katherine A. Kong,Sushma Bharadwaj,Wen-Kai Weng,Melody Smith,Matthew J. Frank,Saurabh Dahiya,
Transplantation and Cellular Therapyno. 2 (2024): S204
Mark P. Hamilton, Erin Craig, Cesar Gentille, Alain Mina,John Tamaresis, Nadia Kirmani, Zachary Ehlinger,Shriya Syal, Zinaida Good,Brian Sworder, Joseph Schroers-Martin,Ying Lu,
Blood Advancesno. 12 (2024): 3314-3326
crossref(2024)
Blood advancesno. 12 (2024): 3001-3012
Blood Advances (2024)
Sushma Bharadwaj, Eric Lau,Mark P Hamilton,Anmol Goyal, Hrishi Srinagesh,Alexandria Jensen, Dasom Lee, Jayasindhu Mallampet, Sarah Elkordy,Shriya Syal, Sunita Patil,Theresa Latchford,
Blood Neoplasia (2024)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn